tradingkey.logo

InspireMD Inc

NSPR
1.990USD
-0.010-0.50%
收盤 12/19, 16:00美東報價延遲15分鐘
83.42M總市值
虧損本益比TTM

InspireMD Inc

1.990
-0.010-0.50%

關於 InspireMD Inc 公司

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

InspireMD Inc簡介

公司代碼NSPR
公司名稱InspireMD Inc
上市日期Apr 12, 2013
CEOSlosman (Marvin L)
員工數量85
證券類型Ordinary Share
年結日Apr 12
公司地址6303 Waterford District Drive
城市MIAMI
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編33126
電話18887766804
網址https://www.inspiremd.com/en/
公司代碼NSPR
上市日期Apr 12, 2013
CEOSlosman (Marvin L)

InspireMD Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Andrea Tommasoli
Mr. Andrea Tommasoli
Chief Operating Officer
Chief Operating Officer
727.69K
--
Dr. Gary S. Roubin, M.D., Ph.D.
Dr. Gary S. Roubin, M.D., Ph.D.
Independent Director
Independent Director
656.42K
+7.89%
Ms. Kathryn Arnold
Ms. Kathryn Arnold
Independent Director
Independent Director
247.53K
--
Mr. Michael Berman
Mr. Michael Berman
Independent Director
Independent Director
189.12K
+17.93%
Mr. Danny L. (Dan) Dearen
Mr. Danny L. (Dan) Dearen
Independent Director
Independent Director
58.02K
--
Mr. Scott R. Ward
Mr. Scott R. Ward
Director
Director
--
--
Mr. Marvin L. Slosman
Mr. Marvin L. Slosman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul S. Stuka
Mr. Paul S. Stuka
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Amir Kohen
Mr. Amir Kohen
Vice President - Finance, Human Resources
Vice President - Finance, Human Resources
--
--
Mr. Shane Gleason
Mr. Shane Gleason
Vice President - Global Marketing, General Manager, North America
Vice President - Global Marketing, General Manager, North America
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Andrea Tommasoli
Mr. Andrea Tommasoli
Chief Operating Officer
Chief Operating Officer
727.69K
--
Dr. Gary S. Roubin, M.D., Ph.D.
Dr. Gary S. Roubin, M.D., Ph.D.
Independent Director
Independent Director
656.42K
+7.89%
Ms. Kathryn Arnold
Ms. Kathryn Arnold
Independent Director
Independent Director
247.53K
--
Mr. Michael Berman
Mr. Michael Berman
Independent Director
Independent Director
189.12K
+17.93%
Mr. Danny L. (Dan) Dearen
Mr. Danny L. (Dan) Dearen
Independent Director
Independent Director
58.02K
--
Mr. Scott R. Ward
Mr. Scott R. Ward
Director
Director
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
OTHER
845.00K
47.53%
Germany
360.00K
20.25%
Italy
324.00K
18.22%
Poland
249.00K
14.00%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Rosalind Advisors, Inc.
9.22%
Nantahala Capital Management, LLC
7.97%
abrdn Inc.
5.86%
Parkman Healthcare Partners LLC
5.76%
Velan Capital Investment Management LP
5.06%
其他
66.14%
持股股東
持股股東
佔比
Rosalind Advisors, Inc.
9.22%
Nantahala Capital Management, LLC
7.97%
abrdn Inc.
5.86%
Parkman Healthcare Partners LLC
5.76%
Velan Capital Investment Management LP
5.06%
其他
66.14%
股東類型
持股股東
佔比
Hedge Fund
30.30%
Individual Investor
17.01%
Investment Advisor/Hedge Fund
16.01%
Private Equity
5.04%
Investment Advisor
2.29%
Research Firm
0.01%
其他
29.34%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
59
17.22M
41.08%
+3.94M
2025Q2
66
22.15M
54.76%
+3.53M
2025Q1
62
18.33M
62.97%
+674.68K
2024Q4
58
17.14M
67.20%
+1.37M
2024Q3
54
16.79M
66.53%
-282.36K
2024Q2
54
16.34M
65.74%
-743.64K
2024Q1
54
14.90M
65.10%
+1.03M
2023Q4
56
13.53M
62.30%
-2.07K
2023Q3
52
13.61M
63.81%
+964.66K
2023Q2
52
12.52M
59.93%
+9.01M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Rosalind Advisors, Inc.
3.91M
9.36%
+1.62M
+70.62%
Aug 04, 2025
Nantahala Capital Management, LLC
2.32M
5.56%
--
--
Jun 30, 2025
Parkman Healthcare Partners LLC
1.24M
2.96%
+63.89K
+5.45%
Jun 30, 2025
Velan Capital Investment Management LP
2.14M
5.14%
+1.24M
+137.13%
Jul 30, 2025
OrbiMed Advisors, LLC
2.13M
5.11%
--
--
Jun 30, 2025
Marshall Wace LLP
1.86M
4.46%
--
--
Jun 30, 2025
Soleus Capital Management, L.P.
1.89M
4.52%
+940.83K
+99.52%
Jun 30, 2025
Slosman Marvin
1.14M
2.73%
+10.33K
+0.92%
Jul 30, 2025
Shore (Craig)
3.40M
8.15%
+2.29M
+205.73%
Apr 15, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
佔比0.01%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1
公告日期
類型
比率
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1
Apr 15, 2021
Merger
15→1

常見問題

InspireMD Inc的前五大股東是誰?

InspireMD Inc的前五大股東如下:
Rosalind Advisors, Inc.
持有股份:3.91M
佔總股份比例:9.36%。
Nantahala Capital Management, LLC
持有股份:2.32M
佔總股份比例:5.56%。
Parkman Healthcare Partners LLC
持有股份:1.24M
佔總股份比例:2.96%。
Velan Capital Investment Management LP
持有股份:2.14M
佔總股份比例:5.14%。
OrbiMed Advisors, LLC
持有股份:2.13M
佔總股份比例:5.11%。

InspireMD Inc的前三大股東類型是什麼?

InspireMD Inc 的前三大股東類型分別是:
Rosalind Advisors, Inc.
Nantahala Capital Management, LLC
abrdn Inc.

有多少機構持有InspireMD Inc(NSPR)的股份?

截至2025Q3,共有59家機構持有InspireMD Inc的股份,合計持有的股份價值約為17.22M,占公司總股份的41.08% 。與2025Q2相比,機構持股有所增加,增幅為-13.68%。

哪個業務部門對InspireMD Inc的收入貢獻最大?

在FY2025Q2,--業務部門對InspireMD Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI